The EMA has granted approval for ProStrakan Group to market SANCUSO (Granisetron Transdermal System) in the EU, with 3M Drug Delivery Systems as the manufacturer. SANCUSO, introduced in the U.S. in 2008, is the only treatment for chemotherapy-induced nausea and vomiting that does not require pills or intravenous administration. The transdermal patch is applied to the upper arm and can be worn for seven days, providing continuous transdermal delivery to control nausea and vomiting.
“SANCUSO is a great illustration of the patient-friendly benefits of transdermal treatment,” said Jim Ingebrand, president and general manager, 3M Drug Delivery Systems. “We look forward to a continued partnership with ProStrakan to bring SANCUSO to new markets.”
“SANCUSO is already proving to be an important option for patients in the U.S. suffering from chemotherapy-induced nausea and vomiting,” said Jamie Blackport, senior vice president of international marketing at ProStrakan. “We are excited about working together with 3M to bring this important treatment to patients in the EU.”
3M Drug Delivery to Manufacture ProStrakan’s SANCUSO
Published September 30, 2013
blog comments powered by Disqus